Project Grant R21AI180901
Award Date
11/21/24
Completion Date
10/31/26
Dollars Obligated
$193K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award of $405,497.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a compact viral system for robust, concurrent CRISPR activation and interference (CRISPRa/i) in primary murine immune cells. The goal is to use this system to map the gene regulatory network controlling BCL11B activation and T cell lineage commitment. Key innovations include CRISPR RNA-scaffolds to recruit...
The federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $972,151 to The Regents of the University of California, San Francisco (UCSF) to conduct systematic genetic investigations of the mechanisms governing immunogenic cell death (ICD). The project aims to enhance understanding of the molecular signals and cellular processes that determine whether phagocytes...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,194,992 to the University of California, San Diego (UC San Diego) to conduct research on the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The key objectives are to: (1) evaluate the role of tissue-resident CD8 T cells in intestinal hyper-permeability and colitis during a sustained viral...
This federal Project Grant award of $643,718 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how interferon-regulatory factors (IRFs) and STAT transcription factors remodel the epigenome and chromosome organization of macrophages to reprogram their immune responses. The research aims to: 1) dissect the roles of innate immune IRFs in de novo enhancer formation, 2)...
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of California, San Diego (UCSD) to investigate the mechanisms regulating immunoglobulin gene rearrangement. The research aims to determine how enhancers and epigenetic modifications orchestrate chromatin dynamics and spatial confinement to enrich interactions between variable...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $971,109 over approximately 3 years starting June 2025 to researchers at the University of California, Merced. The project will study the binding dynamics and oligomerization of DNA sensor proteins AIM2 and IFI16, which are involved in pathogen detection and inflammatory signaling. Using advanced microscopy techniques,...
This Project Grant award, valued at $735,078, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports a 5-year research project to investigate the molecular mechanisms of innate immune memory in humans, with a focus on understanding the epigenetic determinants that enable long-lasting "trained immunity" in myeloid and lymphoid progenitor cells. The...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $200,016 to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year project aims to establish expertise in non-viral CRISPR/Cas9 editing of human hematopoietic stem cells, preclinical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,483,910 to The Washington University in St. Louis to conduct research on novel genetic mechanisms underlying primary immune regulation disorders. The 5-year project, which commenced on April 8, 2025, aims to investigate three key areas: 1) epigenetic mechanisms leading to autosomal random monoallelic expression in...